Welcome to LookChem.com Sign In|Join Free

CAS

  • or

105812-81-5

105812-81-5

Post Buying Request

105812-81-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

  • (3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine,(-)-Trans-paroxol,(-)-trans-4R-(4-fluorophenyl)-3S-hydroxymethyl-1-methylpiperidine,105812-81-5

    Cas No: 105812-81-5

  • No Data

  • 10 Gram

  • Metric Ton/Day

  • Hubei Taiho Chemical Co.,LTD
  • Contact Supplier

105812-81-5 Usage

Chemical Properties

white to light yellow crystal powde

Uses

Different sources of media describe the Uses of 105812-81-5 differently. You can refer to the following data:
1. An intermediate in the synthesis of Paroxetine, a selective serotonin reuptake inhibitor.
2. An intermediate in the synthesis of Paroxetine (P205750), a selective serotonin reuptake inhibitor.

Check Digit Verification of cas no

The CAS Registry Mumber 105812-81-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,8,1 and 2 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 105812-81:
(8*1)+(7*0)+(6*5)+(5*8)+(4*1)+(3*2)+(2*8)+(1*1)=105
105 % 10 = 5
So 105812-81-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H18FNO/c1-15-7-6-13(11(8-15)9-16)10-2-4-12(14)5-3-10/h2-5,11,13,16H,6-9H2,1H3/t11-,13-/m0/s1

105812-81-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail

  • Alfa Aesar

  • (H28137)  (3S,4R)-4-(4-Fluorophenyl)-1-methyl-3-piperidinemethanol, 98%   

  • 105812-81-5

  • 5g

  • 1095.0CNY

  • Detail

  • Alfa Aesar

  • (H28137)  (3S,4R)-4-(4-Fluorophenyl)-1-methyl-3-piperidinemethanol, 98%   

  • 105812-81-5

  • 25g

  • 3365.0CNY

  • Detail

105812-81-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name (3S,4R)-4-(4-Fluorophenyl)-3-Hydroxymethyl-1-Methylpiperidine

1.2 Other means of identification

Product number -
Other names (3S,4R)-4-(4′-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:105812-81-5 SDS

105812-81-5Relevant articles and documents

An efficient and stereoselective synthesis of (3S,4R)-(-)-trans-4- (4′-fluorophenyl)-3-hydroxymethyl-N-methylpiperidine

Somaiah, Sripathi,Sashikanth, Suthrapu,Raju, Veeramalla,Reddy, Karnati Venugopal

, p. 1 - 3 (2011)

An asymmetric conjugate addition reaction between a chiral α,β-unsaturated amido ester and ethyl-N-methylmalonamide has been used as a key step in the synthesis of (3S,4R)-(-)-trans-4-(4′- fluorophenyl)-3-hydroxymethyl-N-methylpiperidine, a key intermediate for (-)-paroxetine.

Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties

-

Page/Page column 35, (2010/11/27)

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. [image]

PROCESS FOR PRODUCING PIPERIDINE COMPOUND

-

Page 9, (2008/06/13)

The present invention.relates to a new process for preparing a pharmaceutical intermediate compound of formula (I). In the formula, Rl represents hydrogen, straight or branched C1-10 alkyl with or without substituent(s), straight or branched C1-10 alkoxy with or without substituent(s), aryl with or without substituent(s), formyl or alkylcarbonyl. Using the process according to the present invention, the intermediate compound for the preparation of aroxetine can be simply prepared with a high product yield and a high purity of 99% or more, without carrying out any dangerous processes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 105812-81-5